Anthem Inc. (NYSE: ANTM) reported a 2% decline in earnings for the first quarter of 2020 due to an increase in income tax expenses as well as higher costs and expenses. The top-line jumped by 21% driven by pharmacy product revenue related to the launch of IngenioRx as well as higher premium revenue.
For full-year 2020, the company expects GAAP EPS to be greater than $21 and adjusted EPS to be greater than $22.30. The company is withdrawing all other guidance metrics for 2020 until visibility improves from the unprecedented uncertainty around the COVID-19 pandemic. In response to the COVID-19 pandemic, the company has temporarily suspended share repurchase activity to enhance liquidity and financial flexibility.
Past Performance
ANTM Q4 2019 Earnings Infographic
Anthem Q3 2019 Earnings Results
Most Popular
Biogen (BIIB) stock research summary | Q3 2021
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) stock research summary | Q3 2021
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key
